search
Back to results

A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema (ELEVATUM)

Primary Purpose

Diabetic Macular Edema

Status
Recruiting
Phase
Phase 4
Locations
International
Study Type
Interventional
Intervention
Faricimab
Sponsored by
Genentech, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetic Macular Edema

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

General Inclusion Criteria:

  • Self-identify as Black/African American, Hispanic/Latino American, or Native American/Alaska Native/Native Hawaiian or other Pacific Islander
  • Diagnosis of diabetes mellitus (type 1 or type 2), as defined by the World Health Organization (WHO) and/or American Diabetes Association, and current regular use of insulin or other injectable drugs (e.g., dulaglutide and liraglutide) and/or oral anti-hyperglycemic agents for the treatment of diabetes
  • Hemoglobin A1c (HbA1c) ≤10% (Note: up to 20% of participants enrolled may have HbA1c up to 12%)
  • For women of childbearing potential: Agreement to remain abstinent (refrain from heterosexual intercourse) or use acceptable contraception methods as defined in the protocol

Ocular Inclusion Criteria for Study Eye:

  • Intravitreal (IVT) treatment-naïve in the study eye (i.e., have not received previous treatment with any anti-VEGF IVT or any corticosteroids periocular or IVT in the study eye)
  • Diabetic macular edema, defined as macular thickening by SD-OCT involving the center of the macula
  • BCVA letter score of 73 to 20 letters (both inclusive) using the ETDRS protocol at the initial testing distance of 4 meters at the baseline visit (Day 1)
  • Clear ocular media and adequate pupillary dilation to allow acquisition of good quality retinal images to confirm diagnosis

Exclusion Criteria:

General Exclusion Criteria:

  • Diabetes mellitus (type 1 or type 2) that is currently medically untreated
  • Previously untreated diabetes mellitus (type 1 or type 2) who started on oral or injectable anti-diabetic medication within 3 months prior to Day 1
  • Any known hypersensitivity to any of the components in the faricimab injection
  • Any known hypersensitivity to any contrast media (e.g., fluorescein), dilating eye drops, disinfectants (e.g., iodine), or any of the anesthetics and antimicrobial preparations used by the patient during the study
  • History of other diseases, other non-diabetic metabolic dysfunction, physical examination finding, or historical or current clinical laboratory finding giving reasonable suspicion of a condition that contraindicates the use of the faricimab or that might affect interpretation of the results of the study or renders the patient at high-risk for treatment complications, in the opinion of the investigator
  • Active cancer within the past 12 months prior to Day 1 except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, and prostate cancer with a Gleason score of ≤6 and a stable prostate-specific antigen for >12 months
  • Stroke (cerebral vascular accident) or myocardial infarction within 12 months prior to Day 1
  • Any febrile illness within 1 week prior to Day 1
  • Pregnant or breastfeeding, or intending to become pregnant during the study or within 3 months after the final dose of faricimab
  • Uncontrolled blood pressure, defined as systolic >180 mmHg and/or diastolic >100 mmHg (while patient is at rest in a sitting position); if a patient's initial reading exceeds these values, a second reading may be taken ≥30 minutes later on the same day
  • Renal failure requiring renal transplant, hemodialysis, or peritoneal dialysis within 6 months prior to Day 1 or anticipated to require hemodialysis or peritoneal dialysis at any time during the study
  • Any condition resulting in a compromised immune system that is likely to impact the aqueous humor inflammatory biomarkers
  • Participation in an investigational trial that involves treatment with any drug or device (with the exception of vitamins or minerals) within 3 months (or 5 half-lives, whichever is longer) prior to Day 1, or during the course of this study
  • Substance abuse occurring within 12 months prior to screening, in the investigator's judgment
  • Use of systemic immunomodulatory treatments (e.g., IL-6 inhibitors) within 6 months or 5 half-lives (whichever is longer) prior to Day 1
  • Use of any systemic corticosteroids within 1 month prior to Day 1
  • Systemic treatment for suspected or active systemic infection
  • Any prior or concomitant systemic anti-VEGF treatment within 6 months or 5 half-lives (whichever is longer) prior to Day 1
  • Use of systemic medications known to be toxic to the lens, retina, or optic nerve (e.g., deferoxamine, chloroquine/hydroxychloroquine, tamoxifen, phenothiazines, or ethambutol) during the 6-months (or 5 half-lives, whichever is longer) prior to Day 1
  • Receiving any treatment that leads to immunosuppression within 6 months (or 5 half-lives, whichever is longer) prior to Day 1
  • Requiring continuous use of any medications or treatments listed as prohibited therapy

Ocular Exclusion Criteria for Study Eye:

  • High-risk proliferative diabetic retinopathy (PDR) in the study eye, using any of the following established criteria for high-risk PDR: Any vitreous or pre-retinal hemorrhage; Neovascularization elsewhere ≥1/2 disc area within an area equivalent to the mydriatic ETDRS 7 fields on clinical examination or on CFPs; Neovascularization at disc ≥1/3 disc area on clinical examination
  • Tractional retinal detachment, pre-retinal fibrosis, vitreomacular traction, or epiretinal membrane involving the fovea or disrupting the macular architecture in the study eye, as evaluated by the central reading center
  • Any history of or ongoing rubeosis iridis
  • Any panretinal photocoagulation or macular laser (focal, grid or micropulse) photocoagulation treatment received in the study eye prior Day 1
  • Any history of treatment with anti-VEGF or any periocular or IVT corticosteroids in the study eye prior to Day 1
  • Any treatment for dry eye disease in the last month prior to Day 1 (e.g., cyclosporine eye drops, lifitegrast eye drops). Lubricating eye drops and ointments are permitted.
  • Any treatment with anti-inflammatory eye drops (e.g., doxycycline) within 1 month prior to Day 1
  • Any intraocular surgery (e.g., cataract surgery) within 3 months prior to Day 1 or any planned surgery during the study
  • Any glaucoma surgery prior to the screening visit
  • History of vitreoretinal surgery/pars plana vitrectomy, corneal transplant, or radiotherapy
  • Uncontrolled glaucoma
  • Any active or suspected ocular or periocular infections on Day 1
  • Any presence of active intraocular inflammation on Day 1 (i.e., Standardization of Uveitis Nomenclature [SUN] criteria >0 or National Eye Institute [NEI] vitreous haze grading >0) or any history of intraocular inflammation
  • Any history of idiopathic, infectious, or noninfectious uveitis
  • Any current ocular condition or other causes of visual impairment for which, in the opinion of the investigator, visual acuity loss would not improve from resolution of macular edema

Ocular Exclusion Criteria for Non-Study Eye:

  • Any history of idiopathic or immune-mediated uveitis
  • Active ocular inflammation or suspected or active ocular or periocular infection on Day 1
  • Currently receiving treatment with brolucizumab or bevacizumab in the non-study eye and is unwilling to switch to a protocol-allowed, non-study eye anti-VEGF treatment during the study
  • Any previous treatment with Iluvien® or Retisert® (fluocinolone acetonide IVT implant) in the non-study eye
  • Non-functioning non-study eye, defined as either: BCVA of hand motion or worse; No physical presence of non-study eye (i.e., monocular); or, Legally blind in the patient's relevant jurisdiction

Sites / Locations

  • Barnet Dulaney Perkins Eye CenterRecruiting
  • Win Retina
  • Retinal Diagnostic CenterRecruiting
  • The Retina Partners
  • Retina Consultants of Orange CountyRecruiting
  • Kaiser Permanente Southern CaliforniaRecruiting
  • Retinal Consultants Medical GroupRecruiting
  • Southwest Retina ConsultantsRecruiting
  • Emerson Clinical Research Institute LLCRecruiting
  • Blue Ocean Clinical ResearchRecruiting
  • Retina Macula Specialists of Miami - LeJeune Road Office
  • Florida Retina InstituteRecruiting
  • Fort Lauderdale Eye Institute
  • University Retina and Macula Associates, PCRecruiting
  • Wilmer Eye Institute Johns Hopkins UniversityRecruiting
  • Md Medical ResearchRecruiting
  • Retina Associates of MichiganRecruiting
  • Saint Louis University
  • Stanley Truhlsen Eye Institute
  • Retina Consultants of NevadaRecruiting
  • Sierra Eye AssociatesRecruiting
  • The Retina Center of New JerseyRecruiting
  • NJ Retina-Teaneck (Clinic)Recruiting
  • Carolina Eye Associates
  • Piedmont Retina SpecialistsRecruiting
  • Atrium Health Wake Forest University School of Medicine - PPDSRecruiting
  • Retina Associates of Cleveland, INCRecruiting
  • Retina Associates of Cleveland - Middleburg Heights LocationRecruiting
  • Scheie Eye InstituteRecruiting
  • Wills Eye HospitalRecruiting
  • Black Hills Eye InstituteRecruiting
  • Charles Retina InstituteRecruiting
  • Austin Clinical Research LLCRecruiting
  • Retina & Vitreous of TexasRecruiting
  • Houston Eye Associates
  • Macula Vitreous Retina Physicians and Surgeons
  • Brown Retina InstituteRecruiting
  • Retina Center of TexasRecruiting
  • Strategic Clinical Research Group, LLCRecruiting
  • Piedmont Eye CenterRecruiting
  • Wagner Kapoor InstituteRecruiting
  • Nairobi HospitalRecruiting
  • City Eye HospitalRecruiting
  • Emanuelli Research and Development Center LLCRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Main Phase: Faricimab

Long-Term Extension Phase: Faricimab

Arm Description

Participants in the main study phase will receive 6-milligram (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) up to Week 20, followed by 6-mg IVT faricimab injections once every 8 weeks (Q8W) up to Week 52. Participants will return for the Week 56 safety follow-up visit after ≥28 days following their last study treatment.

Eligible participants in the U.S. who opt to continue into the long-term extension (LTE) phase of this study will receive 6-mg faricimab IVT injections according to the personalized treatment interval (PTI) dosing algorithm. The minimum and maximum PTIs in the LTE are Q4W and once every 24 weeks (Q24W), respectively.

Outcomes

Primary Outcome Measures

Main Phase: Change in Best Corrected Visual Acuity (BCVA) from Baseline at Week 56, as Measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) Chart at a Starting Distance of 4 Meters
Long-Term Extension Phase: Incidence and Severity of Ocular Adverse Events
Long-Term Extension Phase: Incidence and Severity of Non-Ocular Adverse Events

Secondary Outcome Measures

Main Phase: Percentage of Participants with a Greater Than or Equal to (≥)2-Step ETDRS Diabetic Retinopathy Severity Scale (DRSS) Improvement from Baseline Over Time
Main Phase: Percentage of Participants with a ≥3-Step ETDRS Diabetic Retinopathy Severity Scale (DRSS) Improvement from Baseline Over Time
Main Phase: Percentage of Participants with Absence of Intraretinal Fluid Over Time
Main Phase: Percentage of Participants with Absence of Subretinal Fluid Over Time
Main Phase: Change from Baseline in Central Subfield Thickness Over Time
Main Phase: Percentage of Participants Gaining ≥15 or ≥10 Letters in BCVA from Baseline at Week 56
Main Phase: Percentage of Participants Avoiding a Loss of ≥15 or ≥10 Letters in BCVA from Baseline at Week 56
Main Phase: Incidence and Severity of Ocular Adverse Events
Main Phase: Incidence and Severity of Non-Ocular Adverse Events
Main Phase: Number of Participants Testing Positive for Anti-Drug Antibodies (ADAs) Against Faricimab at Baseline and Anytime During the Study

Full Information

First Posted
January 25, 2022
Last Updated
October 3, 2023
Sponsor
Genentech, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT05224102
Brief Title
A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema
Acronym
ELEVATUM
Official Title
A Phase IV, Multicenter, Open-Label, Single-Arm Study to Investigate Faricimab (RO6867461) Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
February 28, 2022 (Actual)
Primary Completion Date
November 30, 2026 (Anticipated)
Study Completion Date
November 30, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Genentech, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study is designed to investigate treatment response in treatment-naïve underrepresented patients with diabetic macular edema (DME) who are treated with faricimab. The study population will consist of participants ≥18 years of age who self-identify as Black/African American, Hispanic/Latino American, or Native American/Alaska Native/Native Hawaiian or other Pacific Islander; in addition, a cohort of Asian Indian participants will be enrolled in India.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetic Macular Edema

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Model Description
This is a multicenter, open-label, single-arm study with two phases: the main study phase for all eligible patients (up to 56 weeks), followed by an optional long-term extension phase for eligible patients only in the U.S. (up to 100 weeks).
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
218 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Main Phase: Faricimab
Arm Type
Experimental
Arm Description
Participants in the main study phase will receive 6-milligram (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) up to Week 20, followed by 6-mg IVT faricimab injections once every 8 weeks (Q8W) up to Week 52. Participants will return for the Week 56 safety follow-up visit after ≥28 days following their last study treatment.
Arm Title
Long-Term Extension Phase: Faricimab
Arm Type
Experimental
Arm Description
Eligible participants in the U.S. who opt to continue into the long-term extension (LTE) phase of this study will receive 6-mg faricimab IVT injections according to the personalized treatment interval (PTI) dosing algorithm. The minimum and maximum PTIs in the LTE are Q4W and once every 24 weeks (Q24W), respectively.
Intervention Type
Drug
Intervention Name(s)
Faricimab
Other Intervention Name(s)
VABYSMO™, RO6867461, RG7716
Intervention Description
Participants will receive 6-milligram (mg) faricimab intravitreal (IVT) injections, as described in the study arm descriptions for each study phase.
Primary Outcome Measure Information:
Title
Main Phase: Change in Best Corrected Visual Acuity (BCVA) from Baseline at Week 56, as Measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) Chart at a Starting Distance of 4 Meters
Time Frame
From Baseline to Week 56
Title
Long-Term Extension Phase: Incidence and Severity of Ocular Adverse Events
Time Frame
From Day 1 until end of long-term extension (up to 100 weeks)
Title
Long-Term Extension Phase: Incidence and Severity of Non-Ocular Adverse Events
Time Frame
From Day 1 until end of long-term extension (up to 100 weeks)
Secondary Outcome Measure Information:
Title
Main Phase: Percentage of Participants with a Greater Than or Equal to (≥)2-Step ETDRS Diabetic Retinopathy Severity Scale (DRSS) Improvement from Baseline Over Time
Time Frame
Baseline and Weeks 20 and 56
Title
Main Phase: Percentage of Participants with a ≥3-Step ETDRS Diabetic Retinopathy Severity Scale (DRSS) Improvement from Baseline Over Time
Time Frame
Baseline and Weeks 20 and 56
Title
Main Phase: Percentage of Participants with Absence of Intraretinal Fluid Over Time
Time Frame
Baseline and Weeks 4, 8, 12, 16, 20, 28, 36, 44, 48, 52, and 56
Title
Main Phase: Percentage of Participants with Absence of Subretinal Fluid Over Time
Time Frame
Baseline and Weeks 4, 8, 12, 16, 20, 28, 36, 44, 48, 52, and 56
Title
Main Phase: Change from Baseline in Central Subfield Thickness Over Time
Time Frame
Baseline and Weeks 4, 8, 12, 16, 20, 28, 36, 44, 48, 52, and 56
Title
Main Phase: Percentage of Participants Gaining ≥15 or ≥10 Letters in BCVA from Baseline at Week 56
Time Frame
Baseline and Week 56
Title
Main Phase: Percentage of Participants Avoiding a Loss of ≥15 or ≥10 Letters in BCVA from Baseline at Week 56
Time Frame
Baseline and Week 56
Title
Main Phase: Incidence and Severity of Ocular Adverse Events
Time Frame
From Baseline up to Week 56
Title
Main Phase: Incidence and Severity of Non-Ocular Adverse Events
Time Frame
From Baseline up to Week 56
Title
Main Phase: Number of Participants Testing Positive for Anti-Drug Antibodies (ADAs) Against Faricimab at Baseline and Anytime During the Study
Time Frame
From Baseline up to Week 56

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Main Phase General Inclusion Criteria: Self-identify as Black/African American, Hispanic/Latino American, or Native American/Alaska Native/Native Hawaiian or other Pacific Islander; or self-identify as Asian Indian residents of the Indian subcontinent Diagnosis of diabetes mellitus (type 1 or type 2), as defined by the World Health Organization (WHO) and/or American Diabetes Association, and current regular use of insulin or other injectable drugs (e.g., dulaglutide and liraglutide) and/or oral anti-hyperglycemic agents for the treatment of diabetes Hemoglobin A1c (HbA1c) ≤10% (Note: up to 20% of participants enrolled may have HbA1c up to 12%) For women of childbearing potential: Agreement to remain abstinent (refrain from heterosexual intercourse) or use acceptable contraception methods as defined in the protocol Main Phase Ocular Inclusion Criteria for Study Eye: Intravitreal (IVT) treatment-naïve in the study eye (i.e., have not received previous treatment with any anti-VEGF IVT or any corticosteroids periocular or IVT in the study eye) Diabetic macular edema, defined as macular thickening by SD-OCT involving the center of the macula BCVA letter score of 73 to 20 letters (both inclusive) using the ETDRS protocol at the initial testing distance of 4 meters at the baseline visit (Day 1) Clear ocular media and adequate pupillary dilation to allow acquisition of good quality retinal images to confirm diagnosis Long-Term Extension (LTE) Inclusion Criteria: Enrollment in and completion of the main study, without discontinuation from study or study drug treatment Signed LTE-phase Informed Consent Form Ability to comply with the study protocol, in the investigator's judgment For women of childbearing potential: Agreement to remain abstinent (refrain from heterosexual intercourse) or use acceptable contraception methods as defined in the protocol Exclusion Criteria: Main Phase General Exclusion Criteria: Diabetes mellitus (type 1 or type 2) that is currently medically untreated Previously untreated diabetes mellitus (type 1 or type 2) who started on oral or injectable anti-diabetic medication within 3 months prior to Day 1 Any known hypersensitivity to any of the components in the faricimab injection Any known hypersensitivity to any contrast media (e.g., fluorescein), dilating eye drops, disinfectants (e.g., iodine), or any of the anesthetics and antimicrobial preparations used by the patient during the study History of other diseases, other non-diabetic metabolic dysfunction, physical examination finding, or historical or current clinical laboratory finding giving reasonable suspicion of a condition that contraindicates the use of the faricimab or that might affect interpretation of the results of the study or renders the patient at high-risk for treatment complications, in the opinion of the investigator Active cancer within the past 12 months prior to Day 1 except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, and prostate cancer with a Gleason score of ≤6 and a stable prostate-specific antigen for >12 months Stroke (cerebral vascular accident) or myocardial infarction within 12 months prior to Day 1 Any febrile illness within 1 week prior to Day 1 Pregnant or breastfeeding, or intending to become pregnant during the study or within 3 months after the final dose of faricimab Uncontrolled blood pressure, defined as systolic >180 mmHg and/or diastolic >100 mmHg (while patient is at rest in a sitting position); if a patient's initial reading exceeds these values, a second reading may be taken ≥30 minutes later on the same day Renal failure requiring renal transplant, hemodialysis, or peritoneal dialysis within 6 months prior to Day 1 or anticipated to require hemodialysis or peritoneal dialysis at any time during the study Any condition resulting in a compromised immune system that is likely to impact the aqueous humor inflammatory biomarkers Participation in an investigational trial that involves treatment with any drug or device (with the exception of vitamins or minerals) within 3 months (or 5 half-lives, whichever is longer) prior to Day 1, or during the course of this study Substance abuse occurring within 12 months prior to screening, in the investigator's judgment Use of systemic immunomodulatory treatments (e.g., IL-6 inhibitors) within 6 months or 5 half-lives (whichever is longer) prior to Day 1 Use of any systemic corticosteroids within 1 month prior to Day 1 Systemic treatment for suspected or active systemic infection Any prior or concomitant systemic anti-VEGF treatment within 6 months or 5 half-lives (whichever is longer) prior to Day 1 Use of systemic medications known to be toxic to the lens, retina, or optic nerve (e.g., deferoxamine, chloroquine/hydroxychloroquine, tamoxifen, phenothiazines, or ethambutol) during the 6-months (or 5 half-lives, whichever is longer) prior to Day 1 Receiving any treatment that leads to immunosuppression within 6 months (or 5 half-lives, whichever is longer) prior to Day 1 Requiring continuous use of any medications or treatments listed as prohibited therapy Main Phase Ocular Exclusion Criteria for Study Eye: High-risk proliferative diabetic retinopathy (PDR) in the study eye, using any of the following established criteria for high-risk PDR: Any vitreous or pre-retinal hemorrhage; Neovascularization elsewhere ≥1/2 disc area within an area equivalent to the mydriatic ETDRS 7 or 4 fields on clinical examination or on CFPs; Neovascularization at disc ≥1/3 disc area on clinical examination Tractional retinal detachment, pre-retinal fibrosis, vitreomacular traction, or epiretinal membrane involving the fovea or disrupting the macular architecture in the study eye, as evaluated by the central reading center Any history of or ongoing rubeosis iridis Any panretinal photocoagulation or macular laser (focal, grid or micropulse) photocoagulation treatment received in the study eye prior Day 1 Any history of treatment with anti-VEGF or any periocular or IVT corticosteroids in the study eye prior to Day 1 Any treatment for dry eye disease in the last month prior to Day 1 (e.g., cyclosporine eye drops, lifitegrast eye drops). Lubricating eye drops and ointments are permitted. Any treatment with anti-inflammatory eye drops (e.g., doxycycline) within 1 month prior to Day 1 Any intraocular surgery (e.g., cataract surgery) within 3 months prior to Day 1 or any planned surgery during the study Any glaucoma surgery prior to the screening visit History of vitreoretinal surgery/pars plana vitrectomy, corneal transplant, or radiotherapy Uncontrolled glaucoma Any active or suspected ocular or periocular infections on Day 1 Any presence of active intraocular inflammation on Day 1 (i.e., Standardization of Uveitis Nomenclature [SUN] criteria >0 or National Eye Institute [NEI] vitreous haze grading >0) or any history of intraocular inflammation Any history of idiopathic, infectious, or noninfectious uveitis Any current ocular condition or other causes of visual impairment for which, in the opinion of the investigator, visual acuity loss would not improve from resolution of macular edema Main Phase Ocular Exclusion Criteria for Non-Study Eye: Any history of idiopathic or immune-mediated uveitis Active ocular inflammation or suspected or active ocular or periocular infection on Day 1 Currently receiving treatment with brolucizumab or bevacizumab in the non-study eye and is unwilling to switch to a protocol-allowed, non-study eye anti-VEGF treatment during the study Any previous treatment with Iluvien® or Retisert® (fluocinolone acetonide IVT implant) in the non-study eye Non-functioning non-study eye, defined as either: BCVA of hand motion or worse; No physical presence of non-study eye (i.e., monocular); or, Legally blind in the patient's relevant jurisdiction Long-Term Extension (LTE) Exclusion Criteria: Pregnant or breastfeeding, or intending to become pregnant during the study or within 3 months after the final IVT injection of faricimab Presence of other ocular diseases that give reasonable suspicion of a disease or condition that contraindicates the use of faricimab, that might affect interpretation of the results of the LTE, or that renders the patient at high risk for treatment complications Presence of other diseases, metabolic dysfunction, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of faricimab and that might affect interpretation of the results of the LTE, or that renders the patient at high risk of treatment complications History of a severe allergic reaction or anaphylactic reaction to a biologic agent or known hypersensitivity to any component of the faricimab injections, study treatment procedure, dilating drops, or any of the anesthetic and antimicrobial preparations used by a patient during the LTE phase Requirement for continuous use of any medications or treatments indicated as prohibited therapy (as defined in the protocol)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Reference Study ID Number: ML43435 https://forpatients.roche.com/
Phone
888-662-6728 (U.S. Only)
Email
global-roche-genentech-trials@gene.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clinical Trials
Organizational Affiliation
Genentech, Inc.
Official's Role
Study Director
Facility Information:
Facility Name
Barnet Dulaney Perkins Eye Center
City
Mesa
State/Province
Arizona
ZIP/Postal Code
85206
Country
United States
Individual Site Status
Recruiting
Facility Name
Win Retina
City
Arcadia
State/Province
California
ZIP/Postal Code
91006
Country
United States
Individual Site Status
Active, not recruiting
Facility Name
Retinal Diagnostic Center
City
Campbell
State/Province
California
ZIP/Postal Code
95008
Country
United States
Individual Site Status
Recruiting
Facility Name
The Retina Partners
City
Encino
State/Province
California
ZIP/Postal Code
91436
Country
United States
Individual Site Status
Withdrawn
Facility Name
Retina Consultants of Orange County
City
Fullerton
State/Province
California
ZIP/Postal Code
92835-3424
Country
United States
Individual Site Status
Recruiting
Facility Name
Kaiser Permanente Southern California
City
Riverside
State/Province
California
ZIP/Postal Code
92505
Country
United States
Individual Site Status
Recruiting
Facility Name
Retinal Consultants Medical Group
City
Sacramento
State/Province
California
ZIP/Postal Code
95825
Country
United States
Individual Site Status
Recruiting
Facility Name
Southwest Retina Consultants
City
Durango
State/Province
Colorado
ZIP/Postal Code
81303
Country
United States
Individual Site Status
Recruiting
Facility Name
Emerson Clinical Research Institute LLC
City
Washington
State/Province
District of Columbia
ZIP/Postal Code
20011-3010
Country
United States
Individual Site Status
Recruiting
Facility Name
Blue Ocean Clinical Research
City
Clearwater
State/Province
Florida
ZIP/Postal Code
33761-2046
Country
United States
Individual Site Status
Recruiting
Facility Name
Retina Macula Specialists of Miami - LeJeune Road Office
City
Miami
State/Province
Florida
ZIP/Postal Code
33126-5690
Country
United States
Individual Site Status
Completed
Facility Name
Florida Retina Institute
City
Orlando
State/Province
Florida
ZIP/Postal Code
32806-1101
Country
United States
Individual Site Status
Recruiting
Facility Name
Fort Lauderdale Eye Institute
City
Plantation
State/Province
Florida
ZIP/Postal Code
33324
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
University Retina and Macula Associates, PC
City
Oak Forest
State/Province
Illinois
ZIP/Postal Code
60452
Country
United States
Individual Site Status
Recruiting
Facility Name
Wilmer Eye Institute Johns Hopkins University
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21287-0005
Country
United States
Individual Site Status
Recruiting
Facility Name
Md Medical Research
City
Oxon Hill
State/Province
Maryland
ZIP/Postal Code
20745
Country
United States
Individual Site Status
Recruiting
Facility Name
Retina Associates of Michigan
City
Grand Blanc
State/Province
Michigan
ZIP/Postal Code
48439-8301
Country
United States
Individual Site Status
Recruiting
Facility Name
Saint Louis University
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63104-1016
Country
United States
Individual Site Status
Withdrawn
Facility Name
Stanley Truhlsen Eye Institute
City
Omaha
State/Province
Nebraska
ZIP/Postal Code
68105-1119
Country
United States
Individual Site Status
Withdrawn
Facility Name
Retina Consultants of Nevada
City
Las Vegas
State/Province
Nevada
ZIP/Postal Code
89144
Country
United States
Individual Site Status
Recruiting
Facility Name
Sierra Eye Associates
City
Reno
State/Province
Nevada
ZIP/Postal Code
89502
Country
United States
Individual Site Status
Recruiting
Facility Name
The Retina Center of New Jersey
City
Bloomfield
State/Province
New Jersey
ZIP/Postal Code
07003-3000
Country
United States
Individual Site Status
Recruiting
Facility Name
NJ Retina-Teaneck (Clinic)
City
Teaneck
State/Province
New Jersey
ZIP/Postal Code
07666-1704
Country
United States
Individual Site Status
Recruiting
Facility Name
Carolina Eye Associates
City
Southern Pines
State/Province
North Carolina
ZIP/Postal Code
28387
Country
United States
Individual Site Status
Withdrawn
Facility Name
Piedmont Retina Specialists
City
Winston-Salem
State/Province
North Carolina
ZIP/Postal Code
27103-6970
Country
United States
Individual Site Status
Recruiting
Facility Name
Atrium Health Wake Forest University School of Medicine - PPDS
City
Winston-Salem
State/Province
North Carolina
ZIP/Postal Code
27103
Country
United States
Individual Site Status
Recruiting
Facility Name
Retina Associates of Cleveland, INC
City
Beachwood
State/Province
Ohio
ZIP/Postal Code
44122-7340
Country
United States
Individual Site Status
Recruiting
Facility Name
Retina Associates of Cleveland - Middleburg Heights Location
City
Middleburg Heights
State/Province
Ohio
ZIP/Postal Code
44130
Country
United States
Individual Site Status
Recruiting
Facility Name
Scheie Eye Institute
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
Individual Site Status
Recruiting
Facility Name
Wills Eye Hospital
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19107-5109
Country
United States
Individual Site Status
Recruiting
Facility Name
Black Hills Eye Institute
City
Rapid City
State/Province
South Dakota
ZIP/Postal Code
57701
Country
United States
Individual Site Status
Recruiting
Facility Name
Charles Retina Institute
City
Germantown
State/Province
Tennessee
ZIP/Postal Code
38138
Country
United States
Individual Site Status
Recruiting
Facility Name
Austin Clinical Research LLC
City
Austin
State/Province
Texas
ZIP/Postal Code
78750
Country
United States
Individual Site Status
Recruiting
Facility Name
Retina & Vitreous of Texas
City
Bellaire
State/Province
Texas
ZIP/Postal Code
77401-3510
Country
United States
Individual Site Status
Recruiting
Facility Name
Houston Eye Associates
City
Houston
State/Province
Texas
ZIP/Postal Code
77025-1756
Country
United States
Individual Site Status
Withdrawn
Facility Name
Macula Vitreous Retina Physicians and Surgeons
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Individual Site Status
Withdrawn
Facility Name
Brown Retina Institute
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78251-4551
Country
United States
Individual Site Status
Recruiting
Facility Name
Retina Center of Texas
City
Southlake
State/Province
Texas
ZIP/Postal Code
76092
Country
United States
Individual Site Status
Recruiting
Facility Name
Strategic Clinical Research Group, LLC
City
Willow Park
State/Province
Texas
ZIP/Postal Code
76087
Country
United States
Individual Site Status
Recruiting
Facility Name
Piedmont Eye Center
City
Lynchburg
State/Province
Virginia
ZIP/Postal Code
24502
Country
United States
Individual Site Status
Recruiting
Facility Name
Wagner Kapoor Institute
City
Norfolk
State/Province
Virginia
ZIP/Postal Code
23502
Country
United States
Individual Site Status
Recruiting
Facility Name
Nairobi Hospital
City
Nairobi
ZIP/Postal Code
00100
Country
Kenya
Individual Site Status
Recruiting
Facility Name
City Eye Hospital
City
Nairobi
ZIP/Postal Code
00202
Country
Kenya
Individual Site Status
Recruiting
Facility Name
Emanuelli Research and Development Center LLC
City
Arecibo
ZIP/Postal Code
00612
Country
Puerto Rico
Individual Site Status
Recruiting

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
For eligible studies, qualified researchers may request access to individual patient level data through the request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/innovation/process/clinical-trials/data-sharing/).

Learn more about this trial

A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema

We'll reach out to this number within 24 hrs